Onward Medical

Onward Medical N.V. is a medical technology company specializing in neuromodulation therapies to restore movement, function, and independence for individuals with spinal cord injuries. Founded in 2014 and headquartered in Eindhoven, Netherlands, the company develops ARC Therapy platforms, including the FDA-cleared and CE-marked ARC-EX System, a non-invasive external device that delivers targeted electrical stimulation to the cervical spinal cord, enhancing hand strength and sensation in patients with chronic incomplete tetraplegia (C2-C8). Clinical trials like Up-LIFT demonstrate that 90% of participants improved upper limb strength or function, with 87% reporting better quality of life, even decades post-injury. Onward Medical also advances investigational implantable systems: ARC-IM for hemodynamic stability, blood pressure regulation, and mobility; and ARC-BCI, a brain-computer interface enabling thought-driven movement, backed by partnerships with EPFL and CEA-Clinatec, and published in Nature Medicine. With nearly 400 patents and 10 FDA Breakthrough Device Designations, Onward Medical operates across Europe and the US, pioneering solutions in the spinal cord injury treatment landscape.